GrownValve A prosthetic heart valve for adults and children, made from the patient’s own tissue, a replacement heart valve that lasts a lifetime
- Coordinator
- Grownvalve GmbH, Germany
- Runs
- 1 April 2022 to 31 July 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190188598
What the project is doing
In the project's own words, from its summary on CORDIS.
Each year 400,000 people are born with heart valve defects worldwide. Moreover, in the western world, 1 in 8 healthy adults will develop a heart valve problem during their lifetime. Current artificial heart valves made from animal or human donor tissue carry a high risk of tissue rejection, degradation and calcification that limit their lifespan to about 10 years, forcing patients to undergo risky cardiac re-surgery. For children, no dedicated valve product exists, thus, paediatric patients can endure 4-5 surgeries between 0-18 years of age as their bodies outgrow each replacement heart valve.
At GrOwnValve we have developed a paradigm shift in heart valve technology: the first autologous valve, grown from the patient’s own tissue, crafted using medical imaging and a 3D printing technique. Our valve lasts a lifetime, eliminating tissue rejection and surgical risks associated with repeated surgery (bleeding, infection and death).
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Grownvalve GmbH | Berlin | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI